medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2012, Número 4

<< Anterior Siguiente >>

Acta Med 2012; 10 (4)


Actualización sobre el manejo de la diabetes

Saucedo R, Basurto L, Zárate A, Hernández M, Olvera D

Idioma: Español
Referencias bibliográficas: 53
Paginas: 214-219
Archivo PDF: 377.78 Kb.


RESUMEN

El daño de las células beta ocasionado por un trastorno inmunológico resulta en pérdida de la producción de insulina en la diabetes tipo 1, por lo que el tratamiento es necesariamente con el empleo de insulina. Este tipo de diabetes puede aparecer en la juventud; el objetivo esencial es prevenir y/o retardar los riesgos de daño vascular. En la diabetes tipo 2, el mecanismo es multifactorial y versátil; por ello, el manejo es individualizado y la decisión para utilizar los recursos terapéuticos se basa en los riesgos personales de cada paciente. No existe una guía generalizada que se pueda establecer en todos los casos. Independientemente del agente antihiperglucémico que se use no se ha logrado revertir o detener el daño sobre los islotes pancreáticos. El objetivo del manejo de la diabetes es evitar las complicaciones vasculares que son las determinantes de la incapacidad y muerte.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tabák AG, Herder C, Rathman W, Brunner E, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet 2012; 379: 2279-2290.

  2. Cowie CC, Rust KF, Ford ES et al. Full accounting of diabetes and pre-diabetes in the US population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-294.

  3. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ 2011; 343:d7163. doi: 10.1136/bmj.d7163.

  4. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino R. Prediction of incident diabetes mellitus in middle-aged adults: The Framingham Offspring Study. Arch Intern Med 2007; 167: 1068-1074.

  5. Zhang Y, Bandala-Sanchez E, Harrison LC. Revisiting regulatory T cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2012; 19: 271-278.

  6. Langeland LB, Salvesen O, Selle H, Carlsen SM, Fourgner KJ. Short-term continuous glucose monitoring: effects on glucose and treatment satisfaction in patients with type 1 diabetes mellitus; a randomized controlled trial. Int J Clin Pract 2012; 66: 741-747.

  7. Szepietowska B, Głębocka A, Puch U, Górska M, Szelachowska M. Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus. Arch Med Sci 2012; 8: 491-495.

  8. Maruyama T, Nakagawa T, Kasug A, Murata M. Heterogeneity among patients with latent autoimmune diabetes in adults. Diabetes Metab Res Rev 2011; 27: 971-974.

  9. Abdul-Bhani MA, Triphathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 2006; 29: 1130-1139.

  10. Ferrannini E, Nannipieri M, Williams K, Gonzalez C, Haffner SM, Stern MP. Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes 2004; 53: 160-165.

  11. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.

  12. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting β-cell function early in the course of therapyt for type 2 diabetees mellitus. J Clin Endocrinol Metab 2010; 95: 4206-4216.

  13. Schmid R, Vollenweider P, Bastardot F, Vaucher J, Waeber G, Marques-Vidal P. Current genetic data do not improve the prediction of type 2 diabetes mellitus: the CoLaus study. J Clin Endocrinol Metab 2012; 97 (7): E1338-E1341. doi: 10.1210/jc.2011-3412.

  14. Zárate A. Diabetes Mellitus. Bases Terapéuticas. 3a ed. México: Trillas; 2012.

  15. Zárate A, Saucedo R, Basurto L, Hernández M. El nuevo enfoque hacia la diabetes gestacional. Rev Med Inst Mex Seguro Soc 2011; 49: 1-3.

  16. Inzucchi S.E, Bergenstal RM, Buse JE, Diamant M, Ferrannini E, Nauck M et al. Management of gyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia 2012; 55: 1577-1596.

  17. American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care 2012; 35 (suppl 1): S11-S63.

  18. Cefalu WT. American Diabetes Association- European Association for the study of diabetes position statement; due diligence was conducted. Diabetes Care 2012; 35: 1201-1203.

  19. Zárate A., Basurto L, Saucedo R, Hernández-Valencia M. Guía para seleccionar el tratamiento farmacológico en diabetes 2. Rev Med Inst Mex Seguro Soc 2010; 48: 293-296.

  20. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin. Secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.

  21. Sattar N, McConnachie A, Ford I, Gaw A, Cleland SJ, Forouhi NG et al. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. Diabetes 2007; 56: 984-991.

  22. Lauenborg J, Hansen T, Jensen DM, Vestergaard H, Mølsted-Pedersen L, Hornnes P et al. Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danis population. Diabetes Care 2004; 27: 1194-1199.

  23. Gerswtein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overwiew and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305-312.

  24. Rotenstein LS, Kozak BM, Shivers JP, Yarchoan M, Close J, Close KL. The ideal diabetes therapy: what will it look like? How close are we? Clinical Diabetes 2012; 30: 44-52.

  25. Donner T, Muñoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 1405-13.

  26. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011; 13; S53-S64.

  27. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabet Obes Metab 2009; 11: 53-59.

  28. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 26 week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-931.

  29. Steiner S, Hompesch M, Pohl R, Simms P, Flacke F, Mohr T et al. A novel insuline formulation with a more rapid onset of action. Diabetologia 2008; 51: 1602-06.

  30. Forts T, Pfutzner A, Flacke F, Krasner A, Hohberg C, Tarakci E et al. Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes. Diabetes Care 2010; 33: 116-20.

  31. Charbonnel B, DeFronzo R, Davidson J, Schmitz O, Birkeland K, Pirags V et al. A Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab 2010; 95: 2163-2171.

  32. Hollander P, Raslova K, Skjoth TV, Rastam J, Liutkus JF. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 2011; 13: 268-75.

  33. Gross JL, Krammer CK, Leitão CB, Hawkins N, Viana L, Schaan BD. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: A Network Meta-analysis. Ann Intern Med. 2011; 154: 672-679.

  34. Bosi E. Metformin: the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 2009; 11: 3-8.

  35. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2001; 303: 1410-1408.

  36. Ismail-Beigi F. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012; 366: 1319-1327.

  37. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 353: 854-865.

  38. Nathan DM, Buise JB, Davidson MB, Holman RR., Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.

  39. Ismail-Beigi F. Clinical Practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med 2012; 366(14): 1319-1327.

  40. Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes Technol Ther 1999; 1: 267-275.

  41. Khan SE, Haffner SM, Heise M, Herman WH, Holman RR, Jones NP. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.

  42. Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 2008; 5: 73-94.

  43. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007; 23: 919-931.

  44. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-54 studies. Diabetes Obes Metab 2009; 3: 26-34.

  45. Jonh LE, Kane MP, Gbusch RS, Robert A. Expanded use of exenatide in the management of type 2 diabetes. Diabetes Spectrum 2007; 20: 59-63.

  46. Davidson J. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Mayo Clin Proc 2010; 85: S27-S37.

  47. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.

  48. Neumiller JJ, Campbell RK, Wood LD. A review of inhaled technosphere insulin. Ann Pharmacother 2010; 44: 1231-1239.

  49. Rosentock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for thype 2 diabetes: a multicentre randomised trial. Lancet 2010; 375: 2244-2253.

  50. Mingore G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-158.

  51. Zimmet P, Alberti GMM. Surgery or medical therapy for obese patients with type 2 diabetes? N Engl J Med 2012; 366: 1635-1636.

  52. Sjôstrôm L, Lindroos Ak, Peltoken M, Torgerson J, Bouchard C, Carlsson B et al. Lifestyle, diabetes, and cardiovascular risk factors 20 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693.

  53. Sjôstrôm L, Peltoken M, Jacobson P, Sjöström CD, Karason K, Wedel H et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.




2020     |     www.medigraphic.com